APA (7th ed.) Citation

M, M., C, H., S, J., S, G., T, К., A, G., . . . JS, H. (2026). Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19. Clinical therapeutics, 48(3), 232. https://doi.org/10.1016/j.clinthera.2026.01.004

Chicago Style (17th ed.) Citation

M, Marconato, et al. "Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19." Clinical Therapeutics 48, no. 3 (2026): 232. https://doi.org/10.1016/j.clinthera.2026.01.004.

MLA (9th ed.) Citation

M, Marconato, et al. "Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19." Clinical Therapeutics, vol. 48, no. 3, 2026, p. 232, https://doi.org/10.1016/j.clinthera.2026.01.004.